Skip to content

Clinical study of rimazolol tosylate for injection in gastroscopy diagnosis and sedation: a randomized controlled trial.

Clinical study of rimazolol tosylate for injection in gastroscopy diagnosis and sedation: a randomized controlled trial.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032067
Enrollment
Unknown
Registered
2020-04-19
Start date
2020-04-15
Completion date
Unknown
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroscopy

Interventions

Sponsors

Department of Anesthesiology, the First People's Hospital of Lianyungang City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1)18 <= age <= 60 years, regardless of gender; 2)Patients undergoing routine gastroscopy; 3)The ASA score is grade I or II; 4) 18 kg/m2 < BMI < 30kg/m2 5)It is expected that the operation time of gastroscopy does not exceed 15min; 6)Clearly understand, voluntarily participate in the research, and sign the informed consent form by himself.

Exclusion criteria

Exclusion criteria: 1)Requires complicated endoscopic diagnosis and treatment techniques (such as pancreaticobiliary angiography, ultrasound endoscope, endoscopic mucosal resection, endoscopic submucosal dissection, oral endoscopic muscle dissection, etc.) 2)Patients planning to undergo tracheal intubation; 3)Patients diagnosed with difficulty in managing the respiratory tract (improved Markov score of grade IV); 4)Hypertensive patients whose blood pressure has not been satisfactorily controlled by antihypertensive drugs (sitting systolic blood pressure >= 160 mmHg, and / or diastolic blood pressure >= 100 mmHg); 5)Seated systolic blood pressure <= 90 mmHg; 6)Pregnant or lactating women; 7)Those who are allergic to or contraindicated in benzodiazepines, propofol, dacronin and its drug components; 8)Researchers consider patients who are not eligible to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
Sedation success rate;

Secondary

MeasureTime frame
Sedation induction time;Sedation time;Sedative hypotension;Sedation heart rate / arrhythmia;Sedation Hypoxemia / Respiratory Suppression;Incidence of nausea and vomiting;Incidence of vertigo;Patient / Gastroscopy Operator Satisfaction;Body movement rate;BIS;

Countries

China

Contacts

Public Contactzhibin zhao

Department of Anesthesiology, the First People’s Hospital of Lianyungang City

lygzhaozhibin@163.com+86 18961326661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026